The U.S. National Institutes of Health (NIH) and Food and Drug Administration (FDA) now announced the latest plans to transit or shift away from traditional animal testing toward modern alternatives (still not clear), sparking widespread discussion in the research community.
Innovation in Biomedical Research
Under the updated guidance, NIH funding opportunities will prefer or recommend research that incorporates New Approach Methodologies (NAMs) like artificial intelligence, organ-on-a-chip models, and lab-grown tissues, rather than studies based solely on animal models (?). Proponents argue this change could make experiments more predictive of human outcomes (really?) and reduce time and costs in drug development.
Benefits for Labs and Research Budgets
This transition for alternative testing methods may also affect lab operations across the United States (and also globally). Laboratories embracing cutting-edge techniques will seek affordable lab supplies in the US to support in vitro systems, AI tools, and other non-animal workflows. For labs watching their bottom line, finding the cheapest lab supplies in the US without sacrificing quality is becoming increasingly valuable. Resources like Laboes.com can help labs source cost-effective tools and essentials.
As research continues to modernize, prioritizing innovation along with affordability will be a key choice for scientists worldwide.
